国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語(yǔ)Fran?ais
World
Home / World / Americas

US steps up clinical trials for COVID-19 treatment

Xinhua | Updated: 2020-08-07 07:38
Share
Share - WeChat

WASHINGTON -- The US National Institutes of Health (NIH) announced on Thursday the start of a randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in COVID-19 patients.

A nurse wearing personal protective equipment watches an ambulance driving away outside of Elmhurst Hospital during the ongoing outbreak of the coronavirus disease (COVID-19) in the Queens borough of New York, US, April 20, 2020. [Photo/Agencies]

The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the United States and abroad, according to a release of the NIH.

It is the second clinical trial announced by the NIH this week in an effort to step up treatment for COVID-19.

Participants must have laboratory-confirmed SARS-CoV-2 infection with evidence of lung involvement, including a need for supplemental oxygen, abnormal chest X-rays, or illness requiring mechanical ventilation. People with confirmed infection who have mild symptoms or no apparent symptoms will not be included in the study, said the NIH.

They are being randomly assigned in a 1-to-1 ratio to receive either subcutaneous interferon beta-1a plus remdesivir (combination therapy) or remdesivir alone. Neither the participants nor the study team will know who is receiving which treatment regimen.

All participants will receive standard doses of remdesivir and either interferon beta-1a or a placebo. Those in the combination therapy group will receive interferon beta-1a as a 44-microgram subcutaneous injection every other day for a total of four doses during hospitalization.

Those in the remdesivir-only group will receive a matching placebo subcutaneous injection every other day for a total of four doses during hospitalization.

Investigators will evaluate whether time to recovery is shorter in the combination therapy group relative to the remdesivir-only group, said the NIH.

1 2 Next   >>|
Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
科技| 三河市| 共和县| 平遥县| 忻州市| 永仁县| 延边| 雷波县| 阳谷县| 中山市| 庆元县| 武乡县| 六枝特区| 江永县| 闽清县| 岳普湖县| 禹州市| 金平| 台前县| 南投县| 泉州市| 大化| 上杭县| 洛川县| 大洼县| 石渠县| 长子县| 潍坊市| 加查县| 甘南县| 邓州市| 合阳县| 鲜城| 云霄县| 蒲江县| 保亭| 建昌县| 石狮市| 商水县| 南川市| 开远市|